Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, Wallenberg Laboratory, University of Gothenburg, Gothenburg, Sweden.
Fatty liver disease (FLD) is increasingly recognized as a significant health concern with unresolved clinical challenges, having both genetic factors and unexplained heritability.
Research identifies a specific genetic variant (rs71519934) at the PSD3 gene that makes some individuals less susceptible to FLD through a protein change (L186T).
Reducing PSD3 levels in liver cells lowers fat content, and inhibiting this gene in mice protects against FLD, suggesting that targeting PSD3 could lead to new treatments for humans with FLD.